RecruitingPHASE1, PHASE2NCT07179640
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1
Studying Hypophosphatasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alesta Therapeutics
- Intervention
- ALE1(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 18-50 years · All sexes
- Timeline
- 2025 – 2027
Study locations (2)
- New Zealand Clinical Research, Grafton, Auckland, New Zealand
- Fortrea Clinical Research Unit, Leeds, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07179640 on ClinicalTrials.govOther trials for Hypophosphatasia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT06079359Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPPAlexion Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGPHASE3NCT06079372Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase AlfaAlexion Pharmaceuticals, Inc.
- RECRUITINGNCT05234567A Prospective Sub-Study of the Global Hypophosphatasia RegistryAlexion Pharmaceuticals, Inc.
- RECRUITINGNCT05062629United States Hypophosphatasia Molecular Research CenterChildren's Mercy Hospital Kansas City
- ENROLLING BY INVITATIONNCT02306720Registry of Patients With HypophosphatasiaAlexion Pharmaceuticals, Inc.